Form 4 CORCEPT THERAPEUTICS For: Oct 16 Filed by: COOK JOSEPH C JR (10K)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:		3235-0287
Expires:	February 28, 2011
Estimated average burden
hours per response		0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

COOK JOSEPH C JR

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [CORT]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2009

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								304,600	D
Common Stock								1,130,000	I ⁽¹⁾	By Farview Mgmt Co.
Common Stock	10/16/2009		P		209,791 ⁽²⁾	A	$ 1.38	703,984 ⁽³⁾	D
Common Stock	10/16/2009		P		174,826 ⁽²⁾	A	$ 1.38	414,826	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock option (right to buy)

$ 7

⁽⁴⁾

04/17/2012

Common Stock

50,000

Stock Option (right to buy)

$ 7

⁽⁵⁾

11/23/2013

Common Stock

25,000

Stock option (right to buy)

$ 2.7

⁽⁶⁾

12/19/2017

Common Stock

15,000

Warrants

$ 2.77

03/25/2008

03/24/2015

Common Stock

31,570

119,831 ⁽⁷⁾

Stock Option (right to buy)

$ 2.23

⁽⁸⁾

06/10/2018

Common Stock

15,000

Warrants

$ 2.77

03/25/2008

03/24/2015

Common Stock

14,402

By Farview Mgmt Co. ⁽¹⁾

Warrants

$ 2.77

03/25/2008

03/24/2015

Common Stock

25,649

Stock option (right to buy)

$ 0.96

⁽⁹⁾

06/11/2019

Common Stock

30,000

Warrants

$ 1.66

10/16/2009

73,427 ⁽²⁾

10/16/2009

10/16/2012

Common Stock

73,427

$ 0.125

73,427

Warrants

$ 1.66

10/16/2009

61,190 ⁽²⁾

10/16/2009

10/16/2012

Common Stock

61,190

$ 0.125

61,190

Explanation of Responses:

1. These securities are held by Farview Management Co., LLP, of which the reporting person is a general partner.

2. Acquired from the issuer pursuant to a Securities Purchase Agreement dated October 12, 2009.

3. Does not include 350,000 shares of which Mr. Cook disclaims any beneficial ownership interest.

4. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 4/17/2003 and an additional 1.67% of the total option shares on each monthly anniverary of 4/17/2003 thereafter.

5. Immediately exercisable subject to a right of repurchase by Corcept Therapeutics Incorporated that shall lapse at the rate of 20% of the total option shares on 11/23/2004 and an additional 1.67% of the total option shares on each monthly anniverary of 11/23/2004 thereafter.

6. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2007 so that the entirety of the option grant will vest within one year.

7. Does not include 13,995 warrants of which Mr. Cook disclaims any beneficial ownership interest.

8. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 10, 2008 so that the entirety of the option grant will vest within one year.

9. Exercisable with respect to 8.3334% of the total option shares on each monthly anniversary of June 11, 2009 so that the entirety of the option grant will vest on or before the date of Corcept's next Annual Meeting of Stockholders.

	/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated attorney-in-fact	10/21/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Add to Delicious

Digg It

Send by Email

View Comments (0)

Post Comment